Severe iatrogenic bismuth poisoning with bismuth iodoform paraffin paste treated with DMPS chelation

Background. Bismuth iodoform paraffin paste (BIPP) is used for the packing of wound and surgical cavities. Features of both bismuth and iodoform toxicities have been associated with the use of BIPP, but there are no previous reports of 2,3-dimercaptopropane-1-sulphonate (DMPS) chelation therapy for bismuth poisoning secondary to its use. Case Report. A 67-year-old man presented with a pelvic tumor requiring extensive surgical resection. BIPP packing was required post-operatively for surgical wound breakdown. A few days after insertion, the patient developed neurological features of bismuth toxicity (blood and urine bismuth concentrations were 340 μg/L and 2800 μg/L, respectively), which was treated with removal of the BIPP packing and DMPS chelation [27 days of intravenous DMPS (5 mg/kg 4 times daily for 5 days, 5 mg/kg three times daily for 5 days followed by 5 mg/kg twice a day for 17 days) followed by 24 days of oral DMPS (200 mg three times a day for 10 days, followed 200 mg twice daily for 14 days)]. This resulted in improvement in his symptoms and a decline in his pre-chelation bismuth concentration of 480 μg/L to 5 μg/L following chelation. There were no adverse effects during chelation. Conclusions. DMPS chelation appears to be a potentially effective chelating agent in bismuth toxicity.

[1]  M. Stoltenberg,et al.  Retrograde axonal transport of bismuth: an autometallographic study , 2001, Acta Neuropathologica.

[2]  P. Stevens,et al.  Significant elimination of bismuth by haemodialysis with a new heavy-metal chelating agent. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  A. Bridgeman,et al.  Iatrogenic bismuth poisoning. Case report. , 1994, Australian dental journal.

[4]  R. Redfern,et al.  Extradural application of bismuth iodoform paraffin paste causing relapsing bismuth encephalopathy: a case report with CT and MRI studies. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[5]  F. A. de Wolff,et al.  Development of a therapeutic procedure for bismuth intoxication with chelating agents. , 1992, The Journal of laboratory and clinical medicine.

[6]  J. Booth,et al.  Mastoidectomy packs: Xeroform® or BIPP? , 1991, Journal of Laryngology and Otology.

[7]  M. Allwood,et al.  BIPP--how does it work? , 1990, Clinical otolaryngology and allied sciences.

[8]  R. Playford,et al.  Bismuth induced encephalopathy caused by tri potassium dicitrato bismuthate in a patient with chronic renal failure. , 1990, Gut.

[9]  F. Wolff,et al.  Pharmacokinetics and Toxicity of Bismuth Compounds , 1989, Medical toxicology and adverse drug experience.

[10]  A. Donner,et al.  2,3-Dimercapto-1-Propanesulphonate in Heavy Metal Poisoning , 1987, Medical toxicology and adverse drug experience.

[11]  K. Lavelle,et al.  Iodine absorption in burn patients treated topically with povidone‐iodine , 1975, Clinical pharmacology and therapeutics.

[12]  G. Tytgat,et al.  Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid. , 1998, In Analysis.

[13]  F. A. de Wolff,et al.  Bismuth poisoning and chelation. , 1993, Journal of Toxicology Clinical Toxicology.